NASDAQ NMS - GLOBAL MARKET · QNCX
+2.23% · +$0.6600 · Vol 30.4K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Quince Therapeutics Inc

Quince Therapeutics Inc

Biotechnology
$30.20
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
QNCX
Quince Therapeutics Inc
Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is QNCX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading QNCX catalysts
About Quince Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2019
Employees
38
Country
US

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$29.92
Day high
$30.77
Day low
$29.25
Previous close
$29.54
52W high
$880.00
-96.57% from high
52W low
$16.00
2% of range
Market cap
$29.5M
P/E
15.49×
EPS
$1.95
Beta
0.89
Shares out
978K
Volume
30.4K
0.76× rel vol
Avg volume
39.8K
VWAP
$30.07
Price history computed in-house
1W
+29.12%
1M
+72.67%
3M
+17.97%
1Y
-90.85%
YTD
-95.49%
SMA 50 $20.11 · above
SMA 200 $206.14 · below
52W position 2%

QNCX overview

Veridion Score
59
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around QNCX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading QNCX Form 4 filings
Public disclosures

Congress activity in QNCX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for QNCX in the cached public ledger.

Federal contracts

QNCX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for QNCX in this window.
Lobbying spend

QNCX lobbying filings, year to date.

Registered lobbying filings matched to Quince Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for QNCX in this window.
Loading news for QNCX
Analyst ratings
Sovereign unlock shows live analyst consensus for QNCX.
Options
Sovereign unlock shows live options positioning for QNCX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.